Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences Inc (NQ: ENVB )

0.4974 +0.0274 (+5.83%)
Streaming Delayed Price Updated: 10:55 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 279,875
Open 0.5200
Bid (Size) 0.4950 (1)
Ask (Size) 0.4999 (1)
Prev. Close 0.4700
Today's Range 0.4900 - 0.5300
52wk Range 0.4100 - 3.898
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement
From Enveric Biosciences
Via Business Wire
New Patented Psychedelic Drug Brings Hope For Brain Disorder Therapies
Enveric Biosciences has been granted a U.S. patent for EB-002, enhancing protection for treatments targeting brain neurological disorders, including depression and anxiety. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property

Performance

YTD
-60.52%
-60.52%
1 Month
-18.82%
-18.82%
3 Month
-42.23%
-42.23%
6 Month
-50.75%
-50.75%
1 Year
-81.02%
-81.02%

More News

Read More
Enveric Biosciences Announces Patent Granted for Drug Candidate
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Provides Strategic Outlook and Pipeline Update, Elevating EB-003 to Lead Development Candidate
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Participate in BIO International Convention 2024
From Enveric Biosciences
Via Business Wire
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q1 2024
Via InvestorPlace
'Psychedelics-Inspired' Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand
Via Benzinga
Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results
From Enveric Biosciences
Via Business Wire
Microdosing For Depression: Psychedelics Biotech Signs $66.5M Non-Binding Deal To Out-License Novel Psilocin Prodrug Candidate
Via Benzinga
Enveric Biosciences Signs $66.5 Million Non-Binding Term Sheet with MindBio Therapeutics to Out-License Novel Psilocin Prodrug Candidate for Mental Health Disorders
From Enveric Biosciences
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Cannabinoids With Chemotherapy For Breast Cancer: Psychedelics Biotech Inks $61M License Deal For Patented Methods
Via Benzinga
Topics Cannabis
Exposures Cannabis
Enveric Biosciences Announces Signing of Non-Binding Term Sheet with Undisclosed Licensee for Exclusive License to Patented Methods of Treating Breast and Other Cancers Using Cannabinoids
From Enveric Biosciences
Via Business Wire
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Exposures Glyphosate
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023
Via InvestorPlace
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
Via Benzinga
Enveric Biosciences Optimistic On Q4 And Full-Year Results: 'Psychedelic-Inspired' Meds For Future Growth
Via Benzinga
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
From Enveric Biosciences
Via Business Wire
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
Via Benzinga
Topics Economy
Exposures Interest Rates
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Nasdaq Down 100 Points; US Housing Starts Surge In February
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.